- Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition
-
Caroff SN, Hurford I, Bleier HR, Gorton GE, Campbell E
- KMID: 2171057
- Clin Psychopharmacol Neurosci.
- 2015 Aug;13(2):218-221.
- doi: 10.9758/cpn.2015.13.2.218
We describe a case of recurrent, life-threatening, catatonic stupor, without evidence of any associated medical, toxic or mental disorder. This case provides support for the inclusion of a separate category... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in the Pharmacology of Tardive Dyskinesia
-
Caroff SN
- KMID: 2508976
- Clin Psychopharmacol Neurosci.
- 2020 Nov;18(4):493-506.
- doi: 10.9758/cpn.2020.18.4.493
Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine transporter-2 (VMAT2) inhibitors offers hope for reducing the... -
- CITED
-
- Close
- SHARE
-
- Close
- Drug-induced Hyperthermic Syndromes in Psychiatry
-
Caroff SN, Watson CB, Rosenberg H
- KMID: 2513386
- Clin Psychopharmacol Neurosci.
- 2021 Feb;19(1):1-11.
- doi: 10.9758/cpn.2021.19.1.1
Hyperthermia, or extreme elevations in body temperature, can be life-threatening and may be caused by prescription drugs or illegal substances acting at a number of different levels of the neuraxis.... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
-
Caroff SN
- KMID: 2502221
- Clin Psychopharmacol Neurosci.
- 2020 May;18(2):322-326.
- doi: 10.9758/cpn.2020.18.2.322
Objective: Vesicular monoamine transporter-2 (VMAT2) inhibitors have been proven to be effective for the treatment of tardive dyskinesia and their use is likely to increase. The evidence base of published... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Varenicline on Tardive Dyskinesia: A Pilot Study
-
Caroff SN, Gutman AR, Northrop J, Leong SH, Berkowitz RM, Campbell EC
- KMID: 2516187
- Clin Psychopharmacol Neurosci.
- 2021 May;19(2):355-360.
- doi: 10.9758/cpn.2021.19.2.355
Objective: Although evidence implicates striatal cholinergic impairment as a mechanism underlying tardive dyskinesia, trials of nonspecific cholinergic agents have been inconclusive. As a partial agonist at specific nicotinic receptor subtypes,... -
- CITED
-
- Close
- SHARE
-
- Close
- An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia
-
Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B
- KMID: 2526857
- Clin Psychopharmacol Neurosci.
- 2022 Feb;20(1):154-166.
- doi: 10.9758/cpn.2022.20.1.154
Objective: Antipsychotic medications may cause tardive dyskinesia (TD), an often-irreversible movement disorder characterized by involuntary movements that are typically stereotypic, choreiform, or dystonic and may impair quality of life. This... -
- CITED
-
- Close
- SHARE
-
- Close
